OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)
Product name
OPDIVO
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
nivolumab
Registration type
EOI
Indication
Oesophageal Squamous Cell Carcinoma (OSCC)
OPDIVO (concentrated solution for IV infusion), as monotherapy, is indicated for the treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum based chemotherapy.